Robert Harris

Rob Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management. Rob most recently served as Executive Chair of Nuvo Pharmaceuticals Inc. and prior to Nuvo, Rob was the President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, he was the President & CEO of Legacy Pharmaceuticals Inc. Rob also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Rob joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Rob worked in various senior commercial management positions during his twenty-year tenure at Wyeth-Ayerst (now Pfizer Inc.) including its animal health group and has been involved in numerous product launches during his career.

Rob also serves as a member of the Board of Directors of Grey Wolf Animal Health. Previous board experience includes Nuvo Pharmaceuticals Inc., Origin House, Tribute Pharmaceuticals and Aralez Pharmaceuticals Inc.

Rob joined the Trudell Board in November 2018.